Lemaitre Vascular Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lemaitre Vascular Inc (LMAT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lemaitre Vascular Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 263M vs 188,687M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+7.1% annualized vs trailing 12 months), vs accelerating (+3.7%) for its tracked peer group.
- Growth: Lemaitre Vascular Inc generated 10.0% revenue growth year over year in Q2 2026, vs 9.7% for its competitors combined.
- Profitability: Its 27.1% net margin compares with 11.6% for the peer group.
- Scale: Lemaitre Vascular Inc ranks #50 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.2% of industry market cap.
- Peer revenue share: Lemaitre Vascular Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.40M compares with $0.37M for the peer group (1.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LMAT Sales vs. its Competitors, Q2 2026
Lemaitre Vascular Inc reported revenue growth of 10.02 % year on year in Q2 2026, above its competitors' combined revenue growth of 9.71 %.
With a net margin of 27.07 %, Lemaitre Vascular Inc achieved higher profitability than its competitors (11.64 %).
Lemaitre Vascular Inc generated 0.14 % of the combined sales of its peer group, up from 0.14 % a year earlier.
API endpoints for this dataset
Lemaitre Vascular Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Lemaitre Vascular Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lemaitre Vascular Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lemaitre Vascular Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (6) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lemaitre Vascular Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.5% year over year, combined, vs 10.0% for Lemaitre Vascular Inc. Lemaitre Vascular Inc's share of combined industry revenue moved from 0.06% to 0.06%, a gain of 0.00 percentage points.
Lemaitre Vascular Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lemaitre Vascular Inc | Yes | Yes | Yes | No |
| Competitors combined (33) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LMAT Stock Performance relative to its Competitors
LMAT Stock Performance relative to High-Confidence Competitors
LMAT Stock Performance relative to Similar-Size Competitors
LMAT Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Vaso Corporation | 282.9% | Outperformed |
| 2 | Atricure Inc | 282.9% | Outperformed |
| 3 | Livanova Plc | 282.9% | Outperformed |
| 4 | Becton Dickinson And Company | 282.9% | Outperformed |
| 5 | Pulmonx Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lemaitre Vascular Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lemaitre Vascular Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Lemaitre Vascular Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Lemaitre Vascular Inc |
1,984.31 | 262.92 |
 Abbott Laboratories |
191,605.90 | 46,585.00 |
 Medtronic Plc |
130,823.18 | 37,542.00 |
 Stryker Corp |
125,362.19 | 26,300.00 |
 Boston Scientific Corporation |
62,073.00 | 21,070.00 |
 Edwards Lifesciences Corporation |
58,996.06 | 6,512.50 |
| SUBTOTAL | 699,613.41 | 189,079.25 |
Sign in to see all competitors of Lemaitre Vascular Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lemaitre Vascular Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lemaitre Vascular Inc's Competitors Named by the Company
Competitive relationships identified from Lemaitre Vascular Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Abbott | Company report | 85% |
| LifeNet Health | Company report | 85% |
| W. L. Gore | Company report | 85% |
| Baxter | Company report | 85% |
| Edwards Lifesciences | Company report | 85% |
| Terumo | Company report | 85% |
| Becton, Dickinson | Company report | 85% |
| Getinge | Company report | 85% |
| Artivion | Company report | 85% |
| Silk Road Medical | Company report | 85% |
| W. L. Gore & Associates | Company report | 85% |
| Terumo Medical Corporation | Company report | 85% |
| Cardiovascular Systems, Inc. | Company report | 85% |
| Abbott/St. Jude | Company report | 85% |
| CryoLife | Company report | 85% |
| Boston Scientific Corporation | Company report | 85% |
| Medtronic | Company report | 85% |
| Encision Inc | Company report | 85% |
| Utah Medical Products Inc | Company report | 85% |
| Atrion Corporation | Company report | 85% |
| Merit Medical Systems Inc | Company report | 85% |
| Procept Biorobotics Corporation | Company report | 85% |
| Angiodynamics Inc | Company report | 85% |
| Livanova Plc | Company report | 85% |
| Penumbra Inc | Company report | 85% |
| Integra Lifesciences Holdings Corp | Company report | 85% |
| Shockwave Medical Inc | Company report | 85% |
| Avinger Inc | Company report | 85% |
| Abiomed Inc | Company report | 85% |
| Inari Medical Inc | Company report | 85% |
| Vaso Corporation | Company report | 85% |
| Ir med Inc | Company report | 85% |
| Teleflex Incorporated | Company report | 85% |
| Atricure Inc | Company report | 85% |
| Streamex Corp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Lemaitre Vascular Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Lemaitre Vascular Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
| Medtronic Plc | CARDIOVASCULAR 38.34 % |
| Stryker Corp | MedSurg and Neurotechnology 56.20 % |
| Boston Scientific Corporation | Cardiovascular 66.29 % |
| Edwards Lifesciences Corporation | United States 58.74 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Lemaitre Vascular Inc .
Lemaitre Vascular Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lemaitre Vascular Inc | 1,984 | 401,409 | 103,321 |
| Abbott Laboratories | 191,606 | 405,087 | 47,174 |
| Medtronic Plc | 130,823 | 395,179 | 55,463 |
| Stryker Corp | 125,362 | 469,643 | 64,696 |
| Boston Scientific Corporation | 62,073 | 357,119 | 59,220 |
| Edwards Lifesciences Corporation | 58,996 | 407,031 | 62,725 |
| PEERS TOTAL | 697,629 | 371,112 | 36,400 |
Sign in to see all peers for Lemaitre Vascular Inc .
Lemaitre Vascular Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Lemaitre Vascular Inc | US 56.01 % |
| Abbott Laboratories | Non-US 57.70 % |
| Medtronic Plc | United States 49.83 % |
| Stryker Corp | United States 75.92 % |
| Boston Scientific Corporation | United States 64.40 % |
| Becton Dickinson And Company | United States 61.88 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Lemaitre Vascular Inc .
Lemaitre Vascular Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Lemaitre Vascular Inc's industry classification, broader than the peer set above. Market cap in millions of $.Lemaitre Vascular Inc ranks #50 of 218 companies by market capitalization in its industry, holding 0.17 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 50 | Lemaitre Vascular Inc | 1,984 | 0.17 % |
Market cap and industry share for the rest of Lemaitre Vascular Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-06.
Lemaitre Vascular Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 45 | Atricure Inc | 2,861 | 85.15 % |
| 46 | Axogen inc | 2,668 | 109.28 % |
| 47 | Ufp Technologies Inc | 2,363 | 27.56 % |
| 48 | Skinhealth Systems Inc | 2,036 | 789.80 % |
| 49 | Establishment Labs Holdings Inc | 1,234 | 12.3% |
| 50 | Lemaitre Vascular Inc | 1,984 | -5.97 % |
| 51 | Dentsply Sirona Inc | 1,234 | 12.3% |
| 52 | Genedx Holdings Corp | 1,234 | 12.3% |
| 53 | Inspire Medical Systems inc | 1,234 | 12.3% |
| 54 | Kestra Medical Technologies Ltd | 1,234 | 12.3% |
| 55 | Enovis Corp | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Lemaitre Vascular Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Lemaitre Vascular Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 72.76 % | 46.17 % (avg) | +26.6 pp |
| Operating Margin | 29.41 % | industry median | +29.5 pp |
| EBITDA Margin | 40.83 % | -6.98 % (avg) | +47.8 pp |
| Capital Intensity (Capex / Revenue) | 3.48 % | 7.18 % (avg) | -3.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lemaitre Vascular Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 36.0x | 38.2x | -2.3x |
| EV / EBITDA | 24.8x | 18.1x | +6.6x |
| P/B | 6.3x | 4.6x | +1.7x |
| Return on Equity | 16.93 % | industry aggregate | 4.95 % |
| Return on Invested Capital | 7.70 % | -6.82 % (avg) | 14.52 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Lemaitre Vascular Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 4.66 % | 11.05 % | 10.35 % | 19.37 % | 4.68 % | 19.42 % | 13.39 % | 14.00 % |
| Operating Margin | 26.72 % | 18.07 % | 22.25 % | 23.59 % | 16.60 % | 19.02 % | 23.87 % | 27.21 % |
| Return on Invested Capital | 11.36 % | 7.27 % | 7.89 % | 7.85 % | 4.97 % | 6.23 % | 7.39 % | 7.21 % |
| P/E | 22.2x | 40.7x | 38.0x | 38.9x | 49.2x | 39.1x | 49.6x | 34.3x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Lemaitre Vascular Inc's Strategic Group Map
Lemaitre Vascular Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Lemaitre Vascular Inc's trailing-12-month revenue growth of 12.3% and operating margin of 29.4% compares with an average of 11.1% growth and 26.0% margin across its 8 closest peers by combined growth, margin and ROIC -- Lemaitre Vascular Inc sits above that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Lemaitre Vascular Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Lemaitre Vascular Inc falls in the Dog quadrant: relative market share of 0.01x vs its largest competitor, in an industry growing revenue 8.9% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Lemaitre Vascular Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 3.48 % vs industry average 7.18 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Lemaitre Vascular Inc's dedicated Suppliers and Customers pages, not here.
Lemaitre Vascular Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Lemaitre Vascular Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Lemaitre Vascular Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 29.5 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+7.1% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.01x).
Opportunities
- Trades at a lower P/E than the industry average (36.0x vs 38.2x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Lemaitre Vascular Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lemaitre Vascular Inc | 0.81 | 14.19 | 0.42 |
| Abbott Laboratories | 0.42 | 1.50 | 0.44 |
| Medtronic Plc | 0.15 | 2.10 | 0.57 |
| Stryker Corp | 0.50 | 2.08 | 0.65 |
| Boston Scientific Corporation | 0.23 | 1.50 | 0.46 |
| Edwards Lifesciences Corporation | 1.74 | 4.14 | 0.06 |
Sign in to see all peers for Lemaitre Vascular Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lemaitre Vascular Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lemaitre Vascular Inc | Q2 2026 | +10.0 % | +38.3 % |
| Abbott Laboratories | Q2 2026 | +13.0 % | -47.8 % |
| Medtronic Plc | Q2 2026 | +13.7 % | +41.3 % |
| Stryker Corp | Q3 2026 | +7.6 % | -12.3 % |
| Boston Scientific Corporation | Q3 2026 | +1.4 % | -23.2 % |
| Edwards Lifesciences Corporation | Q2 2026 | +13.7 % | -27.2 % |
| PEERS TOTAL | +8.7 % | -8.1 % |
Sign in to see all peers for Lemaitre Vascular Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lemaitre Vascular Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lemaitre Vascular Inc | Q2 2026 | +3.3 % | +72.4 % |
| Abbott Laboratories | Q2 2026 | +9.7 % | -1.0 % |
| Medtronic Plc | Q2 2026 | +13.8 % | -0.2 % |
| Stryker Corp | Q3 2026 | +3.0 % | +26.7 % |
| Boston Scientific Corporation | Q3 2026 | +12.3 % | -0.6 % |
| Edwards Lifesciences Corporation | Q2 2026 | +14.1 % | +35.7 % |
Sign in to see all peers for Lemaitre Vascular Inc .
Lemaitre Vascular Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lemaitre Vascular Inc | 10.90% | 11.20% | 16.93% |
| Abbott Laboratories | 5.56% | 6.45% | 10.41% |
| Medtronic Plc | 5.71% | 6.46% | 10.64% |
| Stryker Corp | 7.66% | 8.63% | 15.61% |
| Boston Scientific Corporation | 7.82% | 9.14% | 13.75% |
| Edwards Lifesciences Corporation | 7.41% | 8.39% | 9.65% |
Sign in to see all peers for Lemaitre Vascular Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lemaitre Vascular Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lemaitre Vascular Inc | 28.38 | 7.55 |
| Abbott Laboratories | 35.35 | 4.11 |
| Medtronic Plc | 299.41 | 3.48 |
| Stryker Corp | 34.70 | 4.77 |
| Boston Scientific Corporation | 18.14 | 2.95 |
| Edwards Lifesciences Corporation | 58.80 | 9.06 |
| PEERS AVERAGE | 37.64 | 3.70 |
Sign in to see all peers for Lemaitre Vascular Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.